Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Under Amgen and AbbVie agreement, rival drug to AbbVie's Humira expected to launch in 2023
Under Amgen and AbbVie agreement, rival drug to AbbVie's Humira expected to launch in 2023
Under Amgen and AbbVie agreement, rival drug to AbbVie's Humira expected to launch in 2023
Submitted by
admin
on September 28, 2017 - 9:50am
Source:
Marketwatch
News Tags:
Amgen
AbbVie
Humira
Amgevita
biosimilars
drug launches
Headline:
Under Amgen and AbbVie agreement, rival drug to AbbVie's Humira expected to launch in 2023
Do Not Allow Advertisers to Use My Personal information
